Executive Chairman Vincent LoPriore and Affiliates Disclose 21.46% Stake in Hepion Pharmaceuticals

summarizeSummary

Executive Chairman Vincent LoPriore and his affiliated entities have disclosed a 21.46% beneficial ownership stake in Hepion Pharmaceuticals, representing a significant investment and strong insider conviction.

check_boxKey Events

• Executive Chairman Discloses Major Stake

  Vincent LoPriore, Executive Chairman, along with Gravitas Capital LP and Invictus Capital Advisors Pension Plan, collectively reported beneficial ownership of 6,250,000 shares, representing 21.46% of Hepion Pharmaceuticals' common stock.

• Significant Insider Investment

  The aggregate purchase price for these shares was approximately $250,000, indicating a substantial investment by the company's leadership.

• Premium Acquisition Context

  This disclosure follows recent insider purchases, including a $250,000 buy by Mr. LoPriore, and a private placement, all executed at $0.04 per share, a significant premium to the current market price of $0.0013.

auto_awesomeAnalysis

Vincent LoPriore, Executive Chairman of Hepion Pharmaceuticals, along with his affiliated entities Gravitas Capital LP and Invictus Capital Advisors Pension Plan, have disclosed a combined beneficial ownership of 21.46% of the company's common stock. This significant stake, acquired for an aggregate purchase price of approximately $250,000, signals strong insider conviction. This disclosure follows a recent private placement and multiple insider purchases, including a $250,000 purchase by Mr. LoPriore, all executed at a substantial premium ($0.04 per share) compared to the current market price. Such a large and committed insider position, especially in a micro-cap company, often indicates a belief in the company's future prospects and can be a positive catalyst for investor sentiment.